CARA Cara Therapeutics, Inc.

+1  (6%)
Previous Close 15.27
Open 15.28
Price To book 8.22
Market Cap 441.49M
Shares 27,303,000
Volume 1,370,969
Short Ratio 21.79
Av. Daily Volume 1,738,000

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiated September 2015. Placed on clinical hold February 2016. Clinical hold released April 2016 with enrollment resuming June 2016. Interim conditional power analysis due 2Q 2017.
IV CR845
Acute pain
Phase 2b trial initiated September, 2016. Data are due 2Q 2017.
Osteoarthritis (OA)
Phase 2/3 completion of enrollment announced November 29, 2016 with top-line data due 1Q 2017.
IV CR845
Uremic pruritus

Latest News

  1. 4 Biotech Stocks to Watch
  2. 4 Biotech Stocks With Jaw-Dropping Growth Potential
  3. 5 Biotech Companies To Watch In 2017
  4. 5 Biotech Companies Set for Major Breakouts In 2017
  5. What Makes Cara Therapeutics So Intriguing?
  7. CARA Therapeutics, Inc. :CARA-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  8. Marijuana Stocks: Sean Williams, GW Pharmaceuticals PLC- ADR (GWPH), And Cara Therapeutics Inc (CARA)
  9. 3 Biotech Stock Rockets With More Fuel in the Tank
  10. Cara Therapeutics to Present at March Medical Meetings
  11. Falling Biotechs: Cara Reports Zero Sales, Ionis Downgraded
  12. Here's Why Shares of Hopeful Marijuana Stock Cara Therapeutics Inc. Went Up in Smoke
  13. Cara Therapeutics Reports Q4 Loss (CARA)
  14. Are Options Traders Betting on a Big Move in Cara Therapeutics, Inc. (CARA) Stock?
  15. CARA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
  16. Cara reports 4Q loss
  17. Cara reports 4Q loss
  18. CARA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
  19. Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
  20. Today's Research Reports on Trending Biotech Tickers: Peregrine Pharmaceuticals and Cara Therapeutics